• The manufacture of lower cost electric vehicles is conditional on the decrease of component costs, with battery packs forming one of the largest parts of their cost structure
• Hillcrest Energy Technologies’ revolutionary inverter technology, which forms an integral part of an electrical vehicle’s powertrain, allows EV’s to improve thermal management and reduce switching losses
• Improved power quality resulting from more efficient power inverters can enable automakers to obtain higher powertrain efficiency and consequently, reduce their battery packs
• Hillcrest Energy Technologies separately seized the opportunity to announce the appointment of Samuel Yik as their new CFO

One of the world’s most inexpensive electric vehicles, the Changli Freeman, currently has a listing price of approximately $1,000. It weighs 323 kilograms, packs up to a 1.2 kW motor, can reach 35km/h and has a claimed range of 40-100 kilometers (https://ibn.fm/ay2wL). By contrast and as of 2018, a Tesla Model 3’s inverter alone was estimated to cost the manufacturer upwards of $1,100 per unit. Hardware costs have come down dramatically in ensuing years; as of 2020, a Model Y inverter was reported to cost approximately $700 per unit, a $400 reduction relative to the 2018 Model 3 version. Nevertheless, component costs remain a key constraint to the further reduction of automotive manufacturing costs, a challenge which Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) is seeking to take on. Hillcrest Energy Technologies, a clean technology company focused around developing transformative power conversion technologies, has centered its energies on creating solutions which have the potential to unlock efficiencies in electrification and maximize the performance of integrated electric systems. “While we have a focus on traction inverter technology for electric vehicles (‘EVs’), the technologies we are developing can also be applied to a wide range of industries to make electrical systems more efficient,” said Hillcrest Chief Technology Officer Ari (https://ibn.fm/Imzjh). In effect, Hillcrest’s revolutionary technology seeks to eliminate traditional design tradeoffs faced across the power industry – in which deploying higher switching frequencies has historically resulted in a greater increase in losses. Since Hillcrest’s inverter technology materially eliminates switching losses, it makes higher switching frequencies feasible, enabling improved output power quality and a reduction in DC-link capacitor size. In turn, this can assist electric vehicle manufacturers by enabling them to reduce motor size, lower torque ripple, and benefit from the increased lifespan of mechanical parts utilized within their traction applications. Over the years, electric vehicle manufacturers have been subject to an accelerated version of Moore’s Law. By some accounts, it costs Tesla $84,000 to manufacture a single vehicle as of 2017 – a cost which has been since been reduced to a reported $36,000 (https://ibn.fm/D3vZ5). Whilst inverters account for less than 2 percent of the total manufacturing cost, they are a crucial component within EV powertrains; a more efficient and lighter inverter could drive cost reductions within the overall battery pack cost structure. Moreover, and with battery systems currently the single most expensive element within most EVs, the manufacture of lower-cost, high-performance battery packs are key to producing affordable electric cars that can go toe to toe with combustion-engine rivals on sticker prices. With Tesla for instance, CEO Elon Musk’s promised improvements in battery cost – which he has pledged to more than half – are seen by investors as critical to the automaker’s quest to usher in an era where it can sell a $25,000 EV for a profit. Hillcrest Energy Technologies has positioned itself and its revolutionary product suite to form part of the cornerstone for the upcoming generation of electric vehicles. As part of its ongoing evolution, Hillcrest recently announced the appointment of Samuel Yik as the company’s Chief Financial Officer (“CFO”). Yik, a Chartered Professional Accountant by training, brings over 10 years of CFO experience in managing publicly listed companies in Canada and the United States and will be instrumental towards contributing to Hillcrest Energy’s future success. “We look forward to having Samuel’s skill and experience on our team,” said Don Currie, CEO of Hillcrest. “We anticipate an acceleration of our progress over the coming year, and Samuel’s extensive knowledge coupled with his ‘can do’ attitude and team-based approach will be key to our continued success.” For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• BiondVax has an exclusive worldwide license to commercialize NanoAbs for the treatment of COVID-19
• The company plans to initiate a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023
• BiondVax has exclusive options for worldwide licenses for NanoAbs to treat other disorders with large, underserved needs
• The company has filed a Registration Statement with the SEC for an underwritten offering of shares

BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

• NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
• NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systems
• The company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products as they move through the regulatory process
• Odyssey’s solutions include a breath-powered intranasal delivery mechanism and synthetic neurosteroids designed to provide rapid-response treatment for patients with concussions and a highly fatal pediatric neurological disease
• Odyssey Health also is developing solutions for heart disease detection, obstructed-airway choking and nerve agent exposure
• The concussion therapeutic solution recently completed Phase I testing successfully and the company is preparing for Phase II efficacy testing in cooperation with military service personnel

Medical technology solutions innovator Odyssey Health (OTC: ODYY) is moving up a rung on the ladder to product success with the formation of a wholly owned pharmaceutical subsidiary focused on developing drugs to treat neurological disorders. Odyssey has been developing and testing drug candidates to combat conditions with unmet needs, with primary area of interest being the development of drug and device combination products that will help people afflicted by central nervous system maladies. This area includes brain concussions, especially affecting military and sports personnel, in addition to a neurological disease with a high mortality rate among pediatric patients, and potentially deadly exposure to nerve gas agents. In September, Odyssey reported completion of its Phase I clinical trial for its concussion drug candidate, PRV-002. The safety trial’s Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) cohorts all found the drug to be well tolerated, and Odyssey is now communicating the trial’s findings to the U.S. Food and Drug Administration (“FDA”) while beginning preparations for a Phase II trial that will seek to provide greater evidence of the drug’s effectiveness, according to a company news release (https://ibn.fm/LpDXa). The new subsidiary, Odyssey Neuropharma, Inc., will help advance Odyssey’s development of neurosteroids such as PRV-002 and PRV-001, which is being designed to combat the neuro-degenerative Niemann-Pick type C disease and has been shown to improve neuromotor function and reduce brain inflammation in pre-clinical studies, according to the company’s most recent news release (https://ibn.fm/dtIcz). Both drugs are fully synthetic and are administered via a breath-powered intranasal delivery device subject to a provisional patent application. The Organophosphate Nerve Agent antidote similarly involves intranasal delivery of powdered oximes (a class of nitrogen-containing organic compounds) to combat the consequences of exposure to chemical weapons. Current use of oximes as an antidote involves multiple injections but Odyssey’s attempt to develop an intranasal product offers the hope of a painless means of delivery that is fast-acting and targeted to the central nervous system. “Odyssey’s lightweight drug device combination can be carried in the pocket of civilians around the world at risk (of nerve agent exposure) as a means of biodefense,” the company’s news release states. Odyssey has also produced other products for potential commercial marketability, such as a device to remove a throat obstruction in a choking person and new technology for the early detection for heart disease. Each product furthers the company’s mission to develop products that fill needs for life-saving solutions to acute brain, cardiovascular and respiratory emergencies. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Flora Growth is a cannabis cultivator and international brand developer with a strong base of operations at its licensed facility in northern Colombia
• Flora recently announced its plans to acquire multi-national operator Franchise Global Health (“FGH”), the latest of its strategic acquisitions designed to boost revenues and expand Flora’s international footprint
• FGH is focused on the German market, where its subsidiary was the first company to sell cannabis
• Germany is in turn expected to provide the companies a launching pad for success in Europe, where opportunity is defined by the fact that currently Germany provides 75 to 80 percent of Europe’s cannabis sales
• Flora has already reported cooperative agreements to increase its product distribution pipeline to Switzerland and the Czech Republic

Cannabis cultivator, brand manufacturer and global distributor Flora Growth (NASDAQ: FLGC) is aiming for continued revenue boosts through strategic acquisitions, announcing Oct. 24 that it will obtain the issued and outstanding shares of multi-national operator Franchise Global Health Inc. as the company positions itself to expand its wholesale cannabis sales and brand distribution operations in Europe. The company stated in its news release that it expects the acquisition to result in at least $3 million of annualized cost synergies within the first year as they eliminate repetitive costs between the two companies (https://ibn.fm/NSGY6). Both companies expect to announce their Q3 financial reports in the near future and while the announcement doesn’t otherwise provide projections of their future performance, Flora’s acquisition strategy has injected significant revenue in recent months, such as when it announced that H1 revenues grew 604 percent YOY to about $15 million (https://ibn.fm/G9uQZ). Flora and Franchise Global Health (stylized FGH) expect to close the all-stock deal in December following presentation of the agreement to FGH shareholders for a vote. “At Flora, we believe that cannabis will dramatically improve the wellbeing of consumers around the globe and that it will become an international trade. Our company exists today to capitalize on that opportunity,” CEO Luis Merchan stated in a video interview about the agreement (https://ibn.fm/JfhPz). “Together we have a very sustainable business,” FGH CEO Clifford Starke stated during the interview. “We have extremely strong revenue performance without executing on really what we’re trying to do, which is become a fully integrated medical cannabis company of high THC products.” One of Flora Growth’s strategic acquisitions earlier this year was consumer wellness brand JustCBD, which increased Flora’s profile to more than half a million wellness consumers and 14,000 points of distribution in the United States at the time. JustCBD’s 79 products registered with the UK’s novel foods standards agency are expected to also help the company expand its operational footprint in Europe and the United Kingdom where CBD is still nascent. Within the United States the company’s NASDAQ listing precludes Flora from participating in the THC (traditional tetrahydrocannabinol cannabis) market however Flora does provide THC and CBD flower and derivatives to international markets thanks to its strong position with a licensed cultivation, extraction and isolation facility in northern Colombia’s fertile climate. FGH was the first company to sell cannabis in Germany, and the companies perceive Germany as they key to entering the rest of Europe. “Our full focus is on Germany,” Starke said. “Our strong position is on the distribution front. … Which, if this cannabis market is going to come to life, which we all believe so, … we’re extremely well positioned to go past Germany into the rest of Europe. It’s very important to understand that 75 to 80 percent of the sales in Europe are accounted in Germany.” Starke added that the acquisition will fill FGH’s strongest need — supply of cannabis. Given Flora’s Colombian cultivation and cost advantages and FGH’s existing relationships with more than 1,200 pharmacies, the companies believe they are well suited to lead the way in medical cannabis in Germany. “When we started up in Germany and going into 2019, we were selling 60, 70, 80 kgs a month quite easily, and unfortunately supply constraints really limited us and now we’re back on path to regain market share,” he said. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing cause
• Lexaria’s patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosing
• The global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026

In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control. According to the Centers for Disease Control and Prevention (“CDC”), in 2020, more than 670,000 deaths in the United States had high blood pressure as a primary or contributing cause (https://ibn.fm/bMiDk). Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that its human clinical study HYPER-H21-4 may be the world’s first study to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (“CBD”) therapy using the company’s patented DehydraTECH(TM)-enabled CBD capsule formulation. According to company CEO Chris Bunka, this is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit. Additionally, DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in liver enzymes throughout the study (https://ibn.fm/EJuhp). “Indeed, of the handful of minor, non-serious adverse events reported, there were nearly as many reported by those patients receiving placebo as those who received DehydraTECH-CBD,” Bunka added. “Consistent with Lexaria’s often-mentioned de-risking strategy, this exceptional safety profile should prove beneficial as we prepare for our planned upcoming Phase Ib Investigational New Drug clinical study to be registered with the U.S. Food and Drug Administration.” The primary safety and efficacy objectives of the HYPER-H21-4 study were achieved, with a significant reduction in blood pressure achieved in 2.5 weeks and over the course of the five weeks of dosing. During the trial, zero serious adverse events were reported. No adverse changes were observed in liver enzymes, which is an important clinical safety biomarker of oral CBD therapy. The study notes that a significant blood pressure decrease was achieved using relatively low doses of DehydraTECH-CBD, a key indicator of the well-established drug delivery efficiencies of the company’s technology – with superior power evidenced through its unique formulation to reduce blood pressure over other oral CBD formulation (https://ibn.fm/fY5jY). The positive findings emphasize Lexaria’s unique position to address the unmet needs of the growing antihypertension drug market. The industry was responsible for $22,557 million in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in $28,797 million by 2026 (https://ibn.fm/JfkSc). Lexaria’s DehydraTECH technology was designed for formulating and delivering lipophilic drugs and active ingredients. It increases effectiveness and improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream. The benefits of Lexaria’s DehydraTECH technology include the following:

• Speeds up the delivery so that effects are felt in minutes
• Increased bioavailability
• Increased brain absorption
• Improves drug potency
• Reduces drug administration costs so that lower doses are necessary
• Masks unwanted taste, eliminating and reducing the need for sweeteners

Since 2016, Lexaria has demonstrated, through its DehydraTECH technology, the ability to increase bio-absorption by up to five to ten times. It has reduced the onset time from one to two hours to just minutes. It will be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, nicotine and more. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder
• Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery
• Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently evaluating the company’s novel therapeutic, designated as SPC-14. Silo first entered a sponsored pact with the university in October 2021 and has recently extended the agreement to continue research for SPC-14 and SPC-15, the company’s therapeutic for stress-induced anxiety disorders (https://ibn.fm/aplTY). “The first steps of our research with Columbia have been positive and we’re happy to extend this research and option pact to continue the progress of SPC-14 as an Alzheimer’s therapeutic and SPC-15 for Stress-Induced Anxiety disorders,” said Silo CEO Eric Weisblum. The agreement extension incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurobiology (in Psychiatry) at the Columbia University Irving Medical Center. With a focus on the molecular mechanisms underlying learning and memory, Dr. Denny’s research aims to uncover whether ketamine and the novel inventions possibly licensed by Silo can improve memory retrieval, halt, or even reverse the disease process. Silo additionally funds researchers at the Translational Psychedelic Program at the University of California San Francisco (“USCF”) to study the effects of psilocybin on various inflammatory conditions. UCSF researchers are aiming to identify the effects of psilocybin on inflammatory markers of the disease. The study recently passed a significant milestone where patients were successfully dosed and blood samples were collected (https://ibn.fm/oo8Qk). Silo Pharma aims to differentiate its treatments through enhanced delivery mechanisms that improve efficacy while reducing side effects. The company formulations leverage proprietary Z-pod(TM) technology developed by partner Zylö Therapeutics that use highly engineered amorphous silica particles that encapsulate compounds to improve treatment performance. Preclinical studies demonstrated that the jointly developed delivery method and formulation can hold and distribute therapeutics in a time-released manner to provide targeted delivery, increased bioavailability (https://ibn.fm/tliga). Silo Pharma Inc. is fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, rheumatoid arthritis, and other rare neurological disorders. The company partners with leading institutions such as Columbia University, the University of California San Francisco (“UCSF”), and the University of Maryland, Baltimore (“UMB”) to develop treatments the company believes will transform healthcare and improve patient outcomes. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• Commercial buildings in the United States consume 35% of all electricity in the country while accounting for 16% of emissions in the country. Buildings, in general, account for over 60% of emissions, with large business centers responsible for as much as 70%
• With 80% of building stock that will be standing in 2050 already built, the only remaining solution is to retrofit these buildings with renewable energy sources to meet the 2050 net zero targets
• Correlate is looking to meet this demand and solve the challenges associated with it by offering a more cost-effective approach with its finance program
• It prides itself on its transparency and fair pricing, which, its management argues, are enablers of green energy adoption within different sectors, including the real estate industry
• By laying down, the groundwork for the energy transition, Correlate is carving out a decent market share in the North American market and is growing its customer numbers, as evidenced by its $100 million opportunity pipeline in commercial projects and $20 million in awarded backlog

It is estimated that over 60% of carbon emissions within cities in the United States come from buildings, and some of the large business centers account for as much as 70%. With 80% of building stock that will be standing in 2050 already built, the only remaining solution to this growing issue is retrofitting these buildings with renewable energy sources, mainly since new buildings and construction alone will not get society to the 2050 net zero targets (https://ibn.fm/tFlFj). Correlate Infrastructure Partners (OTCQB: CIPI), a portfolio-scale real estate platform, recognizes the problem at hand and the challenges associated with making existing buildings achieve their net-zero targets. With its focus on renewable energy, specifically solar, the company is offering a more cost-effective approach towards reducing buildings’ and companies’ carbon footprint while also allowing them to be self-sustaining from an energy standpoint. According to the Office of Energy Efficiency and Renewable Energy, commercial buildings in the United States consume 13.6 quads of electricity, equivalent to 35% of all the electricity consumed in the country. In addition, they generate as much as 826 million metric tons of carbon dioxide emissions, or 16% of all emissions in the country. This makes decarbonizing and electrifying the built environment vital to achieving the net zero carbon goal (https://ibn.fm/hfSxJ). With 2050 closing in, retrofitting rates will need to exceed 3% per year to achieve the set targets, and Correlate is looking to satisfy that need. Most buildings are opting for solar power installation, mainly because of their affordability, given the 89% drop in the cost of solar power components over the past ten years (https://ibn.fm/MnAnW). However, even with the price decline, the upfront cost associated with retrofitting entire buildings is hefty for real estate owners, posing a significant challenge with renewable energy adoption and reducing a building’s overall carbon footprint. Correlate recognizes this issue, and through its finance platform, it offers commercial and industrial facilities access to clean electrification solutions, ranging from locally-sited solar, energy storage, and even electric vehicle (“EV”) infrastructure and intelligent efficiency measures. In addition, the company prides itself on its transparency and fair pricing, which, its management argues, are enablers of green energy adoption within different sectors, including, but not limited to, the real estate industry. With 2050 closing in, building owners, investors, and occupiers are urged to transition to renewable energy soon. While mandatory regulations are set to ramp up during the second half of the decade (2025-2030) as the climate emergency intensifies, these parties are encouraged not to wait for regulations to kick in before making the transition. Correlate is laying down the groundwork for this changeover and setting up systems and infrastructure geared toward making retrofitting as easy, affordable, and seamless as possible. By doing so, it is carving out a substantial market share within the North American market. It is also growing its customer numbers, evidenced by its $100 million opportunity pipeline in commercial projects and $20 million in awarded backlog. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

After various successful shows across North and South America, Alternative Products Expo is coming to Tampa, Florida, this November 10-10, at Tampa’s Convention Center. The event has something for everyone. It features over 250 industry vendors, 20+ speakers from across the industry, and many contests and giveaways.

Starting some years ago with a series of successful Vape events, the Alt Pro Expo team ventured into organizing events for the alternative products sector. These products have significantly disrupted traditional markets, offering people different choices regarding entertainment and health.

Among these categories, attendees can find options like kratom, dietary supplements, hemp derivatives, nootropics, vapes & nicotine replacements, energy beverages, mushrooms, and so on.

The show offers a phenomenal opportunity for investors, as they can discover the untapped potential of new products that have just been released in the market. From high-profile companies to rising SMBs there will be a wide range of business opportunities for those looking to connect with the right partner.

The show provides the alternative products industry with an excellent platform for businesses to come forward and share their business ideas and have some fun.

“We have invested heavily in our show to make the experience of our exhibitors and attendees better. The $80k we’ll be giving away is aimed at bringing new products into retail stores and helping exhibitors make new connections. General admission attendees can also get a piece of the action and spend at the show as well on a company they want to try out.” – Nicole Beiner, Director of Business Operations & Marketing.

Here are some of the activities attendees can find at the event:

• Over $80K in cash in giveaways during the whole length of the event
• There will be money guns and booths giving out cash for attendees to spend at the show
• A Fun Zone with cornhole, ping-pong, and more activities, along with a Cantina to grab some drinks
• Free product samples from the vendors exhibiting at the event
• An unmatched atmosphere that focuses not only on business opportunities but on having a good time

The show will host numerous speakers with impressive backgrounds from the CBD and Alternative products industry, sharing their experiences, strategies, and tips.

To learn more, please visit https://ibn.fm/AI01n.

• Accurate, powerful vision, mission and value statements can distinguish companies from their competition
• The inability to agree upon, articulate these key elements can cause serious problems for a company
• Adherence to guiding principles and values serves all in arriving at the most effective and collaborative decisions, notes SHRG

Aligning a company’s vision, mission and values with its culture seems like an obvious thing, but it’s not unusual to have a disconnect between the two, reports a recent Direct Selling News (DSN) article (https://ibn.fm/GQkuj). Yet companies with powerful, accurate vision, mission and value statements, such as Sharing Services Global (OTCQB: SHRG), often distinguish themselves from others operating in the same space.

“Who are you? It sounds like a silly question. Or the beginning of an awkward introduction,” writes Paul Adams, author of the DSN article. “When I ask the question to a group of executives, I’m asking about who they are as a company. What do you stand for? How do you act? What expectations do you have for each other and the team around you? But, the answers I get are—normally—about the products, the opportunity or the way you want people in the field to think of the company.”

The inability to articulate vision (the company’s big goal), mission (how the company will achieve the vision) and values (what a company cherishes and how it treats people) can cause serious problems, writes Adams. He has been involved in the direct-selling channel for more than three decades and has helped hundreds of companies invent, reinvent and solidify their messaging, strategy and execution.

Time spent clearly identifying these key elements of a business cannot be underestimated. “Think of the vision, mission and values as the guardrails for your business,” Adams suggests. “If you know what matters most and what is nonnegotiable, you can easily say no to ideas that don’t fit. More importantly, you can say yes and run faster inside the lane you’ve created for yourself when everyone knows what matters most.”

Clear vision, mission and values have guided Sharing Services Global in its commitment to promote health, wealth and happiness by reshaping how entrepreneurs succeed today. Recognizing what Adams teaches (https://ibn.fm/mRkEm), the company notes that “the quality of internal decisions determines the quality and success of outcomes. Emotion decision making can often tilt the decision-making objectives. Adherence to guiding principles and values serve all in arriving at the most effective and collaborative decision.”

The company states its guiding principles and values as follows:

• We exist to serve people
• Technology must always be a strength
• Less is more
• Research is the foundation to excellence in decision making
• Quality is the foundation to sustainable success
• Speed is important
• No compromise

Sharing Services doesn’t just talk the talk of values and principles; the company is adamant about transforming these statements into real-world and real-life action as it works to capture profitable market share through acquisition, new business entry and management of diverse business models. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force.

For more information, visit the company’s websites at www.SHRGInc.com, www.TheHappyCo.com and www.ShareHapiTravel.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• President Biden issued a pardon for federally incarcerated inmates with minor marijuana possession charges, urging governors to do the same at the state level
• The President also requested a reclassification of cannabis, as it is currently listed above other drugs which are key factors in the overdose epidemic
• Flora Growth, through its Colombian cultivation, is producing a higher quality product at lower-than-average cost margins due to the country’s stance on cannabis regulations

With midterm elections right around the corner, voters in five states – Arkansas, Maryland, Missouri, North Dakota, and South Dakota – will determine the legality of recreational marijuana use within each state on voting day. If passed, these states will join 19 states, two territories, and D.C., which have embraced recreational marijuana use legalization. Currently, 37 states, three territories, and D.C. already recognize the legal use of cannabis for medicinal reasons. According to Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, “When you look at ballot campaigns in the past, you’ll see that this is an issue that crosses traditional party lines. We anticipate similar outcomes this November” (https://ibn.fm/9BJbc).

Early in October, President Biden released a formal statement on his goals for marijuana reform across the country. Citing how criminal records can impose unnecessary barriers to employment, housing, and educational opportunities – more disproportionately to those people of color who are more often arrested, prosecuted, and convicted. His announcement included three steps – pardoning all prior federal offenses of simple marijuana possession, urging the governors to do the same in their respective states, and initiating a review by the Secretary of Health and Human Services and the Attorney General to review the classification of marijuana, which is classified higher than drugs currently driving the overdose epidemic (https://ibn.fm/J9zGk).

President Biden’s request for the reclassification of marijuana and the pardons issued at the federal level is helping to change the landscape of the cannabis industry. An international cannabis company, Flora Growth (NASDAQ: FLGC), is focused on cannabis brand building, leveraging natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. The company operates one of the largest outdoor cultivation facilities in the world with the aim of marketing higher-quality premium products at below-market prices. Flora Growth offers low-cost cannabis cultivation, an expansive brand and product portfolio, and a strategic global distribution platform. The NASDAQ listing of the company precludes it from participating in the US domestic market for adult use presently due to federal prohibitions.

The global cannabis cultivation market was valued at $323.9 billion in 2022. The market is expected to grow at a CAGR of 21.4% from 2022 to 2030, resulting in a market valuation of $1,844.1 billion by 2030. The growing interest in legalizing cannabis for medicinal and recreational use is a driving factor in the market’s growth (https://ibn.fm/oeLUe). Liberalization of laws regarding cannabis cultivation, especially hemp cultivation, has created opportunities in the market – which Flora Growth is leveraging, with the cultivation of its product at a key Colombian farm for international markets.

Flora Growth’s Colombian cultivation provides key advantages, including location, climate, and natural resources – all of which reduce the costs of traditional cultivation. With Colombia’s administration focused on progressive cannabis regulations, Flora Growth can produce high-quality, high-margin products leveraging Colombia’s geo-advantageous location. Over 70% of all cut flowers imported into the US come from Colombia – but Flora Growth is taking it one step further by reducing the associated costs, coming in at just $.06 per gram.

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC